Skip to main content
. 2018 Apr 30;56(2):105–112. doi: 10.3347/kjp.2018.56.2.105
Group 1: 10 infected non-treated mice, maintained as infection control group.
Group 2: 10 mice infected and treated with MTZ (10 mg/kg) as standard drug.
Group 3: 20 mice infected and treated with AVA. They were subdivided into group 3A (10 mice) given a dose of 20 mg/kg/day and group 3B (10 mice) given a dose of 40 mg/kg/day.
Group 4: 20 mice infected and treated with combinational therapy of AVA and MTZ. They were subdivided into group 4A (10 mice), given AVA at a dose of 20 mg/kg/day and MTZ (10 mg/kg) and group 4B (10 mice), given AVA at a dose of 40 mg/kg/day and MTZ (10 mg/kg).
Group 5: 50 mice non-infected and treated with MTZ and AVA to act as drug control group, divided in to: 5A: 10 mice received MTZ 10 mg/kg. 5B: 10 mice received AVA 20 mg/kg, 5C: 10 mice received AVA 40mg/kg. 5D: 10 mice received MTZ 10mg/kg and AVA 20 mg/kg, 5E: 10 mice received MTZ 10 mg/kg and AVA 40 mg/kg.
Group 6: 10 non-infected non-treated mice, maintained as control group.